Charles Duncan
Stock Analyst at Cantor Fitzgerald
(3.55)
# 880
Out of 5,113 analysts
217
Total ratings
47.83%
Success rate
23.21%
Average return
Main Sectors:
Stocks Rated by Charles Duncan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Reiterates: Overweight | n/a | $7.13 | - | 6 | Mar 28, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Overweight | $28 | $27.51 | +1.78% | 21 | Feb 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Downgrades: Neutral | $140 → $150 | $171.00 | -12.28% | 6 | Feb 26, 2025 | |
| AXSM Axsome Therapeutics | Reiterates: Overweight | $153 | $186.98 | -18.17% | 22 | Feb 19, 2025 | |
| GHRS GH Research | Initiates: Overweight | $14 | $16.73 | -16.32% | 1 | Feb 13, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Overweight | n/a | $90.39 | - | 1 | Jan 10, 2025 | |
| BHVN Biohaven | Reiterates: Overweight | n/a | $13.76 | - | 17 | Dec 17, 2024 | |
| STOK Stoke Therapeutics | Reiterates: Overweight | n/a | $30.05 | - | 7 | Dec 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Overweight | $51 → $58 | $36.76 | +57.78% | 8 | Oct 30, 2024 | |
| ALKS Alkermes | Maintains: Overweight | $48 → $43 | $33.95 | +26.66% | 5 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $64.93 | - | 7 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $10.34 | - | 15 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $137.37 | +12.83% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $16.54 | - | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 | $20.93 | +67.22% | 6 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $8.10 | +60.49% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.46 | - | 2 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.97 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $24.45 | +39.06% | 9 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $52 → $50 | $54.95 | -9.01% | 3 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $5 | $6.86 | -27.11% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $0.66 | +506.06% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.07 | +273.83% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $58 | $42.24 | +37.31% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $1,100 | $1.25 | +87,900.00% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $80 | $5.42 | +1,376.01% | 5 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.04 | +188.46% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $11 | $5.30 | +107.55% | 2 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $12 | $7.80 | +53.85% | 2 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $146 → $168 | $9.75 | +1,623.08% | 6 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $3.32 | +502.41% | 1 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $200 | $33.54 | +496.30% | 3 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $1.75 | +128.57% | 3 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $2.32 | +934.48% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $372 → $144 | $1.56 | +9,130.77% | 6 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $1.41 | +183.69% | 2 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 → $39 | $71.29 | -45.29% | 4 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $15 | $41.30 | -63.68% | 4 | Feb 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $0.40 | - | 3 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $5.38 | +3,245.72% | 1 | Oct 9, 2017 |
COMPASS Pathways
Mar 28, 2025
Reiterates: Overweight
Price Target: n/a
Current: $7.13
Upside: -
ACADIA Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $28
Current: $27.51
Upside: +1.78%
Jazz Pharmaceuticals
Feb 26, 2025
Downgrades: Neutral
Price Target: $140 → $150
Current: $171.00
Upside: -12.28%
Axsome Therapeutics
Feb 19, 2025
Reiterates: Overweight
Price Target: $153
Current: $186.98
Upside: -18.17%
GH Research
Feb 13, 2025
Initiates: Overweight
Price Target: $14
Current: $16.73
Upside: -16.32%
Bright Minds Biosciences
Jan 10, 2025
Initiates: Overweight
Price Target: n/a
Current: $90.39
Upside: -
Biohaven
Dec 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.76
Upside: -
Stoke Therapeutics
Dec 10, 2024
Reiterates: Overweight
Price Target: n/a
Current: $30.05
Upside: -
Harmony Biosciences Holdings
Oct 30, 2024
Maintains: Overweight
Price Target: $51 → $58
Current: $36.76
Upside: +57.78%
Alkermes
Oct 25, 2024
Maintains: Overweight
Price Target: $48 → $43
Current: $33.95
Upside: +26.66%
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $64.93
Upside: -
Sep 30, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.34
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $155
Current: $137.37
Upside: +12.83%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.54
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $35
Current: $20.93
Upside: +67.22%
Aug 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $8.10
Upside: +60.49%
Jul 30, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.46
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.97
Upside: -
Mar 22, 2024
Reiterates: Overweight
Price Target: $34
Current: $24.45
Upside: +39.06%
Oct 24, 2023
Assumes: Overweight
Price Target: $52 → $50
Current: $54.95
Upside: -9.01%
Sep 22, 2023
Initiates: Overweight
Price Target: $5
Current: $6.86
Upside: -27.11%
Sep 7, 2023
Reiterates: Overweight
Price Target: $4
Current: $0.66
Upside: +506.06%
Aug 22, 2023
Reiterates: Overweight
Price Target: $4
Current: $1.07
Upside: +273.83%
Aug 22, 2023
Reiterates: Overweight
Price Target: $58
Current: $42.24
Upside: +37.31%
Aug 22, 2023
Reiterates: Overweight
Price Target: $1,100
Current: $1.25
Upside: +87,900.00%
Aug 16, 2023
Reiterates: Overweight
Price Target: $80
Current: $5.42
Upside: +1,376.01%
Aug 14, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.04
Upside: +188.46%
Dec 6, 2022
Downgrades: Neutral
Price Target: $16 → $11
Current: $5.30
Upside: +107.55%
Nov 22, 2022
Upgrades: Overweight
Price Target: $9 → $12
Current: $7.80
Upside: +53.85%
Jun 8, 2022
Maintains: Overweight
Price Target: $146 → $168
Current: $9.75
Upside: +1,623.08%
Feb 18, 2022
Initiates: Overweight
Price Target: $20
Current: $3.32
Upside: +502.41%
Feb 18, 2022
Initiates: Overweight
Price Target: $200
Current: $33.54
Upside: +496.30%
Apr 20, 2021
Downgrades: Neutral
Price Target: $8 → $4
Current: $1.75
Upside: +128.57%
Oct 23, 2020
Initiates: Overweight
Price Target: $24
Current: $2.32
Upside: +934.48%
Sep 28, 2020
Downgrades: Neutral
Price Target: $372 → $144
Current: $1.56
Upside: +9,130.77%
Jun 1, 2020
Maintains: Overweight
Price Target: $3 → $4
Current: $1.41
Upside: +183.69%
May 4, 2020
Reiterates: Overweight
Price Target: $35 → $39
Current: $71.29
Upside: -45.29%
Feb 21, 2020
Reiterates: Neutral
Price Target: $14 → $15
Current: $41.30
Upside: -63.68%
Nov 15, 2017
Upgrades: Overweight
Price Target: n/a
Current: $0.40
Upside: -
Oct 9, 2017
Initiates: Overweight
Price Target: $180
Current: $5.38
Upside: +3,245.72%